The program aims to improve the efficacy of patient infusion logs and reporting.
Catalyst Biosciences, Inc recently reported updated interim data from their phase 2/3, multinational clinical study of marzeptacog alfa (MarzAA), a subcutaneous (administered under the skin) factor VIIa therapy.
Dr. Li is planning for a career in non-malignant hematology, with a long-term career goal of becoming an academic hematologist and clinical researcher in the field of coagulation medicine.
The trials is for uniQure investigational gene therapy treatment for patients with severe and moderately severe hemophilia B.
NHLB is currently seeking feedback on hemophilia inhibitors measures proposed for inclusion in the PhenX Toolkit (consensus measures for Phenotypes and eXposures).
The donation includes product as well as integrated care development training.
Connections for Learning and Anna DeSimone travel grant applications are now open.
Becas de viaje disponibles para la Conferencia de Trastornos Hemorrágicos de NHF.
The case was ruled in favor of Genentech.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car